Antidepresan İlaçlar ve Cinsel İşlevler

Authors

Osman Gerçek
https://orcid.org/0000-0002-8710-7171
Recep Uzun

Synopsis

Sexual dysfunction may occur as a symptom of depressive disorders or as a consequence of antidepressant treatment. Antidepressant-induced sexual dysfunction may manifest as decreased sexual desire, difficulty with arousal, erectile dysfunction, reduced lubrication, altered genital sensitivity, delayed or absent orgasm, and ejaculatory disturbances. In particular, strongly serotonergic medications such as selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and clomipramine are associated with a higher risk of sexual adverse effects. In contrast, bupropion, mirtazapine, agomelatine, and vortioxetine generally have a more favorable sexual tolerability profile. However, comparisons among antidepressants are influenced by the assessment scale used, treatment dose, duration of follow-up, severity of depression, and baseline sexual functioning. Antidepressant-induced sexual dysfunction may negatively affect quality of life, intimate relationships, and treatment adherence. Therefore, sexual functioning should be assessed before treatment, monitored regularly throughout treatment, and any emerging problems should be managed in accordance with the patient’s priorities. The main management strategies include watchful waiting, dose reduction, switching to an antidepressant with a lower risk of sexual adverse effects, adjunctive bupropion, the use of phosphodiesterase type 5 inhibitors in appropriate patients, and psychosexual interventions.

References

Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21.

Zini J, Turecki G. Antidepressant-Induced Sexual Dysfunction in Adults: A Targeted Scoping Review and Clinical Update. J Clin Psychopharmacol. 2026.

Gonçalves WS, Gherman BR, Abdo CHN, Coutinho ESF, Nardi AE, Appolinario JC. Prevalence of sexual dysfunction in depressive and persistent depressive disorders: a systematic review and meta-analysis. Int J Impot Res. 2023;35(4):340-9.

Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329-34.

Wang WF, Chang L, Minhas S, Ralph DJ. Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007;120(11):1000-6.

Tran FD, Bichai GH, Kravetz Z, Meriden Z. Management of Antidepressant-Induced Sexual Dysfunction: A Literature Review. Cureus. 2025;17(8):e90170.

Sathianathen NJ, Hwang EC, Mian R, Bodie JA, Soubra A, Lyon JA, et al. Selective Serotonin Re-Uptake Inhibitors for Premature Ejaculation in Adult Men: A Cochrane Systematic Review. World J Mens Health. 2022;40(2):257-63.

Wang Q, Xu Z, Chen X, Liu L, Liu X. Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: A systematic review and network meta-analysis. Andrology. 2025;13(6):1333-45.

Fornaro M, Cattaneo CI, De Berardis D, Ressico FV, Martinotti G, Vieta E. Antidepressant discontinuation syndrome: A state-of-the-art clinical review. Eur Neuropsychopharmacol. 2023;66:1-10.

Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67-85.

Alipour-Kivi A, Eissazade N, Shariat SV, Salehian R, Soraya S, Askari S, et al. The effect of drug holidays on sexual dysfunction in men treated with selective serotonin reuptake inhibitors (SSRIs) other than fluoxetine: an 8-week open-label randomized clinical trial. BMC Psychiatry. 2024;24(1):67.

Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3(1):13-37.

Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145-80.

Montejo AL, Becker J, Bueno G, Fernández-Ovejero R, Gallego MT, González N, et al. Frequency of Sexual Dysfunction in Patients Treated with Desvenlafaxine: A Prospective Naturalistic Study. J Clin Med. 2019;8(5).

Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand. 2006;114(6):384-97.

Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012;12(12):Cd009138.

O’Sullivan C, Froyman C. Nortriptyline safer than amitriptyline? Can Fam Physician. 2018;64(9):634-6.

Nurnberg HG, Levine PE. Spontaneous remission of MAOI-induced anorgasmia. Am J Psychiatry. 1987;144(6):805-7.

Philipp M, Tiller JW, Baier D, Kohnen R. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups. Eur Neuropsychopharmacol. 2000;10(5):305-14.

Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;2013(5):Cd003382.

Huecker MR, Smiley A, Saadabadi A. Bupropion. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2026, StatPearls Publishing LLC.; 2026.

Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med. 2015;12(10):2036-48.

Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242-52.

Fagiolini A, González-Pinto A, Miskowiak KW, Morgado P, Young AH, Vieta E. Role of trazodone in treatment of major depressive disorder: an update. Ann Gen Psychiatry. 2023;22(1):32.

La Torre A, Giupponi G, Duffy D, Conca A. Sexual dysfunction related to psychotropic drugs: a critical review--part I: antidepressants. Pharmacopsychiatry. 2013;46(5):191-9.

Chivers ML, Seto MC, Lalumière ML, Laan E, Grimbos T. Agreement of self-reported and genital measures of sexual arousal in men and women: a meta-analysis. Arch Sex Behav. 2010;39(1):5-56.

Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci. 2024;33:e40.

Clayton AH, Croft HA, Handiwala L. Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med. 2014;126(2):91-9.

Safak Y, Inal Azizoglu S, Alptekin FB, Kuru T, Karadere ME, Kurt Kaya SN, et al. Antidepressant- associated sexual dysfunction in outpatients. BMC Psychiatry. 2025;25(1):317.

Streed CG, Jr. Health Communication and Sexual Orientation, Gender Identity, and Expression. Med Clin North Am. 2022;106(4):589-600.

Elnazer HY, Baldwin DS. Structured review of the use of the Arizona sexual experiences scale in clinical settings. Hum Psychopharmacol. 2020;35(3):e2730.

Published

November 17, 2026

License

License